StemCell Therapy

SAN FRANCISCO, Jan. 21, 2020 (GLOBE NEWSWIRE) -- Pendulum Therapeutics, an evidence-based microbiome company, announced today the formation of its Scientific Advisory Board (SAB) and Medical Advisory Board (MAB). The two boards comprise experts in metabolic disease, computational biology, genetics and microbiology who are faculty members at world-leading medical institutions.

Pendulum Therapeutics is the first and only microbiome company to apply the discoveries of high-resolution, long-read DNA sequencing to the development and commercialization of microbiome interventions targeting specific diseases. Advisory board members are working closely with Pendulums leadership team as the company seeks to apply genomic discoveries to the continued development of microbiome interventions.

We are incredibly fortunate to have these world-class experts support our work by providing ongoing guidance to our scientific and medical strategy and tactics, said Colleen Cutcliffe, co-founder and CEO. Together, we have created the first microbiome intervention for type 2 diabetes with both scientific and medical data. We are excited to work with our advisors, both collectively and individually, to further our mission of making millions of lives healthier through microbiome-targeted medical probiotics.

Ive long believed that the next major medical breakthroughs would come from analyzing and deciphering the complex world of the microbiome through rigorous excellent DNA science, said Eric Schadt, dean for Precision Medicine at the Icahn School of Medicine at Mount Sinai, and founder and CEO of Sema4. Pendulum Therapeutics has built a microbiome discovery and development platform that stands at the center of this new field of medical innovation and is poised to revolutionize how we address chronic diseases through paradigm-shifting medical innovations.

Pendulums Scientific Advisory Board (SAB):

Pendulums Medical Advisory Board (MAB):

About Pendulum TherapeuticsPendulum Therapeutics is the first and only microbiome company to apply the discoveries of high-resolution, long-read DNA sequencing to the development and commercialization of microbiome interventions targeting specific diseases. Pendulums proprietary innovation platform enables identification of microbiome mechanisms of action and rapid translation from discovery and development through human clinical validation. Founded in 2012 by a diverse team of scientists with deep microbiology, biochemistry, computational and clinical expertise, Pendulum has raised $57 million to date. Sequoia Capital led its Series B with repeat participation from Mayo Foundation, True Ventures, Khosla Ventures, AME Cloud Ventures and others. Formerly Whole Biome, Pendulum Therapeutics is headquartered in San Francisco. For more information, please visit http://www.Pendulum.co.

View original post here:
Pendulum Therapeutics Announces Formation of Scientific and Medical Advisory BoardsGlobally Recognized Metabolic Experts and Industry Luminaries...

This entry was posted on January 22, 2020 at 4:44 pm and is filed under Integrative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |